Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $112 from $102 and keeps an Outperform rating on the shares. Both icotrokinra and rusfertide are likely to be approved this year, which will validate Protagonist’s discovery and development capabilities, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $113 from $108 at Barclays
- Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
- Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright
- Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
- Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships